Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0105
+0.0005 (+5.00%)
Streaming Delayed Price
Updated: 11:31 AM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
33,000
Open
0.0103
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0100
Today's Range
0.0100 - 0.0105
52wk Range
0.0060 - 0.0431
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
June 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Performance
YTD
-53.33%
-53.33%
1 Month
-12.50%
-12.50%
3 Month
-51.16%
-51.16%
6 Month
-64.88%
-64.88%
1 Year
-61.11%
-61.11%
More News
Read More
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
June 10, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
April 23, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
April 18, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
March 27, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Corporate Update
March 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
February 01, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
January 16, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
January 10, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
December 20, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
December 18, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
November 21, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
November 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
October 17, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
October 11, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
August 22, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
July 28, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
July 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 30, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
May 02, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
April 18, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
